CRDL
Cardiol Therapeutics Inc.
Price Chart
Latest Quote
$1.21
-0.02 (-1.63%)
Current Price
| Previous Close | $1.23 |
| Open | $1.28 |
| Day High | $1.28 |
| Day Low | $1.18 |
| Volume | 1,412,875 |
Stock Information
Note: Financial values converted from CAD to USD
| Shares Outstanding | 115.27M |
| Total Debt | $83K |
| Cash Equivalents | $19.74M |
| Net Income | $-25.93M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $139.48M |
| EPS (TTM) | $-0.27 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $111.92M |
| Income | $-25.93M |
| Book/sh | $0.15 |
| Cash/sh | $0.24 |
| Employees | 18 |
Financial Ratios
| Quick Ratio | 3.93 |
| Current Ratio | 4.39 |
| Debt/Eq | 0.48 |
Returns & Margins
| ROA | -78.25% |
| ROE | -173.96% |
Ownership
| Insider Ownership | 2.38% |
| Institutional Ownership | 24.66% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.07 |
| P/B | 7.87 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $7.33 |
Technical Indicators
| SMA20 | $1.07 |
| SMA50 | $1.16 |
| SMA200 | $1.11 |
| RSI | 67.49 |
| ATR | 0.0801 |
| Shares Float | 96.50M |
| Short Float | 1.98% |
| Short Ratio | 5.95 |
| Volatility | 0.51 |
| Rel Volume | 1.95 |
Performance History
| Week | +19.80% |
| Month | +14.15% |
| Quarter | -14.18% |
| 6 Months | +24.10% |
| YTD | +21.73% |
| Year | -6.92% |
| 3 Years | +45.78% |
| 5 Years | -48.51% |
| 10 Years | -67.66% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $1.21 | 1,412,875 |
| 2026-07-16 | $1.23 | 2,146,500 |
| 2026-07-15 | $1.11 | 719,100 |
| 2026-07-14 | $1.15 | 3,334,100 |
| 2026-07-13 | $1.06 | 1,273,100 |
| 2026-07-10 | $1.01 | 361,600 |
| 2026-07-09 | $0.99 | 365,400 |
| 2026-07-08 | $1.00 | 365,800 |
| 2026-07-07 | $1.01 | 537,300 |
| 2026-07-06 | $1.07 | 532,500 |
| 2026-07-02 | $1.05 | 412,500 |
| 2026-07-01 | $1.05 | 315,100 |
| 2026-06-30 | $1.06 | 302,500 |
| 2026-06-29 | $1.03 | 341,700 |
| 2026-06-26 | $1.04 | 439,800 |
| 2026-06-25 | $1.04 | 521,400 |
| 2026-06-24 | $1.03 | 337,800 |
| 2026-06-23 | $1.05 | 218,400 |
| 2026-06-22 | $1.06 | 280,900 |
| 2026-06-18 | $1.06 | 258,500 |
About Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
đ° Latest News
Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation
Simply Wall St. âĸ 2026-05-15T16:22:54Z
Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S.
MT Newswires âĸ 2026-04-28T12:07:56ZCardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise
MarketBeat âĸ 2026-04-15T10:15:39Z
Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trial
MT Newswires âĸ 2026-04-01T18:24:19ZCardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conference
MarketBeat âĸ 2026-03-08T23:02:26Z
Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards?
Zacks âĸ 2026-03-03T13:07:00Z
Analysts Expect Breakeven For Cardiol Therapeutics Inc. (TSE:CRDL) Before Long
Simply Wall St. âĸ 2026-01-12T15:38:16Z
TSX Penny Stocks To Watch In October 2025
Simply Wall St. âĸ 2025-10-21T19:05:13Z
Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics
Zacks âĸ 2025-10-15T10:19:00Z
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
Zacks âĸ 2025-10-14T14:57:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $24,458,530 | $28,706,701 | $21,229,262 | $29,461,653 |
| Other Income Expense | $-163,202 | $1,714,855 | $-271,734 | $6,534,097 |
| Net Non Operating Interest Income Expense | $517,734 | $850,540 | $1,452,892 | $882,107 |
| Operating Expense | $24,458,530 | $28,706,701 | $21,229,262 | $29,461,653 |
| General And Administrative Expense | $14,394,352 | $18,453,791 | $11,091,071 | $15,946,657 |
| Other Non Operating Income Expenses | - | $20,116 | $106,725 | $117,205 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-24,103,998 | $-26,141,306 | $-20,048,104 | $-22,045,449 |
| Net Interest Income | $517,734 | $850,540 | $1,452,892 | $882,107 |
| Interest Income | $517,734 | $850,540 | $1,452,892 | $882,107 |
| Normalized Income | $-23,940,796 | $-27,836,045 | $-19,669,646 | $-28,462,340 |
| Net Income From Continuing And Discontinued Operation | $-24,103,998 | $-26,141,306 | $-20,048,104 | $-22,045,449 |
| Net Income Common Stockholders | $-24,103,998 | $-26,141,306 | $-20,048,104 | $-22,045,449 |
| Net Income | $-24,103,998 | $-26,141,306 | $-20,048,104 | $-22,045,449 |
| Net Income Including Noncontrolling Interests | $-24,103,998 | $-26,141,306 | $-20,048,104 | $-22,045,449 |
| Net Income Continuous Operations | $-24,103,998 | $-26,141,306 | $-20,048,104 | $-22,045,449 |
| Pretax Income | $-24,103,998 | $-26,141,306 | $-20,048,104 | $-22,045,449 |
| Interest Income Non Operating | $517,734 | $850,540 | $1,452,892 | $882,107 |
| Operating Income | $-24,458,530 | $-28,706,701 | $-21,229,262 | $-29,461,653 |
| Depreciation Amortization Depletion Income Statement | $72,687 | $265,933 | - | - |
| Depreciation And Amortization In Income Statement | $72,687 | $265,933 | - | - |
| Amortization Of Intangibles Income Statement | $0 | $149,930 | - | - |
| Depreciation Income Statement | $72,687 | $116,002 | - | - |
| Per Share | ||||
| Diluted EPS | $-0.28 | $-0.36 | $-0.31 | $-0.35 |
| Basic EPS | $-0.28 | $-0.36 | $-0.31 | $-0.35 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-24,222,640 | $-30,135,508 | $-20,673,791 | $-35,721,808 |
| Total Unusual Items | $-163,202 | $1,694,739 | $-378,458 | $6,416,892 |
| Total Unusual Items Excluding Goodwill | $-163,202 | $1,694,739 | $-378,458 | $6,416,892 |
| Reconciled Depreciation | $72,687 | $265,933 | $177,012 | $156,737 |
| EBITDA (Bullshit earnings) | $-24,385,842 | $-28,440,769 | $-21,052,250 | $-29,304,916 |
| EBIT | $-24,458,530 | $-28,706,701 | $-21,229,262 | $-29,461,653 |
| Diluted Average Shares | $62,000,611 | $51,009,061 | $45,945,294 | $44,550,391 |
| Basic Average Shares | $62,000,611 | $51,009,061 | $45,945,294 | $44,550,391 |
| Diluted NI Availto Com Stockholders | $-24,103,998 | $-26,141,306 | $-20,048,104 | $-22,045,449 |
| Gain On Sale Of Security | $-163,202 | $1,694,739 | $-378,458 | $6,416,892 |
| Amortization | $0 | $149,930 | - | - |
| Research And Development | $9,991,490 | $9,986,978 | $10,138,190 | $13,514,996 |
| Selling General And Administration | $14,394,352 | $18,453,791 | $11,091,071 | $15,946,657 |
| Other Gand A | $7,820,167 | $9,247,737 | $11,091,071 | $15,946,657 |
| Salaries And Wages | $6,574,184 | $9,206,054 | - | - |
Fetched: 2026-07-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $12,742,130 | $17,624,931 | $19,982,430 | $36,995,941 |
| Total Assets | $16,834,825 | $22,710,507 | $26,157,848 | $44,210,084 |
| Total Non Current Assets | $84,169 | $139,406 | $390,164 | $420,900 |
| Current Assets | $16,750,655 | $22,571,102 | $25,767,684 | $43,789,184 |
| Prepaid Assets | $1,324,952 | $517,811 | $671,002 | $1,060,492 |
| Receivables | $161,218 | $257,741 | $199,475 | $342,255 |
| Other Receivables | $121,499 | $186,206 | $97,736 | $192,635 |
| Accounts Receivable | $39,719 | $71,535 | $101,740 | $149,620 |
| Cash Cash Equivalents And Short Term Investments | $15,264,485 | $21,795,550 | $24,897,207 | $42,386,437 |
| Cash And Cash Equivalents | $15,264,485 | $21,795,550 | $24,897,207 | $42,386,437 |
| Goodwill And Other Intangible Assets | - | $0 | $149,930 | $210,117 |
| Other Intangible Assets | - | - | $149,930 | $210,117 |
| Debt | ||||
| Total Debt | $89,465 | $112,992 | $124,259 | $51,938 |
| Long Term Debt And Capital Lease Obligation | $62,134 | $89,465 | $112,992 | $15,982 |
| Current Debt And Capital Lease Obligation | $27,331 | $23,527 | $11,267 | $35,955 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,092,695 | $5,085,577 | $6,025,488 | $7,004,027 |
| Total Non Current Liabilities Net Minority Interest | $62,134 | $89,465 | $112,992 | $15,982 |
| Current Liabilities | $4,030,561 | $4,996,112 | $5,912,496 | $6,988,044 |
| Other Current Liabilities | $1,523,739 | - | $169,757 | $299,279 |
| Payables And Accrued Expenses | $2,479,491 | $4,972,585 | $5,731,472 | $6,652,809 |
| Equity | ||||
| Common Stock Equity | $12,742,130 | $17,624,931 | $20,132,360 | $37,206,058 |
| Total Equity Gross Minority Interest | $12,742,130 | $17,624,931 | $20,132,360 | $37,206,058 |
| Stockholders Equity | $12,742,130 | $17,624,931 | $20,132,360 | $37,206,058 |
| Retained Earnings | $-151,865,215 | $-127,761,217 | $-101,619,910 | $-81,571,807 |
| Other Equity Interest | - | - | $2,507,318 | $2,507,318 |
| Other | ||||
| Ordinary Shares Number | $71,456,984 | $58,878,571 | $46,579,055 | $45,645,552 |
| Share Issued | $71,456,984 | $58,878,571 | $46,579,055 | $45,645,552 |
| Tangible Book Value | $12,742,130 | $17,624,931 | $19,982,430 | $36,995,941 |
| Invested Capital | $12,742,130 | $17,624,931 | $20,132,360 | $37,206,058 |
| Working Capital | $12,720,094 | $17,574,990 | $19,855,188 | $36,801,140 |
| Capital Lease Obligations | $89,465 | $112,992 | $124,259 | $51,938 |
| Total Capitalization | $12,742,130 | $17,624,931 | $20,132,360 | $37,206,058 |
| Additional Paid In Capital | $20,729,447 | $17,566,971 | $13,389,715 | $11,109,328 |
| Capital Stock | $143,877,897 | $127,819,176 | $105,855,238 | $105,161,218 |
| Common Stock | $143,877,897 | $127,819,176 | $105,855,238 | $105,161,218 |
| Long Term Capital Lease Obligation | $62,134 | $89,465 | $112,992 | $15,982 |
| Current Capital Lease Obligation | $27,331 | $23,527 | $11,267 | $35,955 |
| Net PPE | $84,169 | $139,406 | $240,234 | $210,784 |
| Accumulated Depreciation | $-623,391 | $-550,703 | $-468,096 | $-351,271 |
| Gross PPE | $707,560 | $690,109 | $708,330 | $562,055 |
| Leases | $169,096 | $169,096 | $169,096 | $169,096 |
| Other Properties | $366,484 | $366,484 | $399,880 | $265,269 |
| Machinery Furniture Equipment | $171,980 | $154,529 | $139,355 | $127,690 |
| Properties | $0 | $0 | $0 | $0 |
Fetched: 2026-07-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-17,018,961 | $-17,876,371 | $-17,992,255 | $-19,453,530 |
| Operating Activities | ||||
| Operating Cash Flow | $-17,001,511 | $-17,861,197 | $-17,946,419 | $-19,400,284 |
| Cash Flow From Continuing Operating Activities | $-17,001,511 | $-17,861,197 | $-17,946,419 | $-19,400,284 |
| Operating Gains Losses | $-91,015 | $-1,516,829 | $-672,633 | $-5,562,888 |
| Investing Activities | ||||
| Capital Expenditure | $-17,450 | $-15,174 | $-45,836 | $-53,246 |
| Investing Cash Flow | $-17,450 | $-15,174 | $-45,836 | $-53,246 |
| Cash Flow From Continuing Investing Activities | $-17,450 | $-15,174 | $-45,836 | $-53,246 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $11,430,467 | $15,220,398 | $0 | $0 |
| Financing Cash Flow | $11,075,433 | $13,427,747 | $-39,467 | $-38,439 |
| Cash Flow From Continuing Financing Activities | $11,075,433 | $13,427,747 | $-39,467 | $-38,439 |
| Net Other Financing Charges | $-339,984 | $-1,889,564 | - | - |
| Net Common Stock Issuance | $11,430,467 | $15,220,398 | $0 | $0 |
| Common Stock Issuance | $11,430,467 | $15,220,398 | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $-39,467 | $-29,600 | $-39,467 | $-38,439 |
| End Cash Position | $15,263,942 | $21,794,774 | $24,896,320 | $42,384,927 |
| Beginning Cash Position | $21,794,774 | $24,896,320 | $42,384,927 | $59,795,929 |
| Effect Of Exchange Rate Changes | $-587,304 | $1,347,078 | $543,115 | $2,080,968 |
| Changes In Cash | $-5,943,527 | $-4,448,624 | $-18,031,722 | $-19,491,970 |
| Proceeds From Stock Option Exercised | $24,418 | $126,514 | $0 | $0 |
| Net Issuance Payments Of Debt | $-39,467 | $-29,600 | $-39,467 | $-38,439 |
| Net Long Term Debt Issuance | $-39,467 | $-29,600 | $-39,467 | $-38,439 |
| Long Term Debt Payments | $-39,467 | $-29,600 | $-39,467 | $-38,439 |
| Net PPE Purchase And Sale | $-17,450 | $-15,174 | $-45,836 | $-53,246 |
| Purchase Of PPE | $-17,450 | $-15,174 | $-45,836 | $-53,246 |
| Change In Working Capital | $-522,659 | $-663,938 | $-389,053 | $4,096,683 |
| Change In Payables And Accrued Expense | $187,934 | $-758,860 | $-921,304 | $3,189,251 |
| Change In Prepaid Assets | $-807,113 | $153,185 | $389,477 | $959,510 |
| Change In Receivables | $96,520 | $-58,264 | $142,774 | $-52,078 |
| Changes In Account Receivables | $31,815 | $30,204 | $47,879 | $-102,762 |
| Other Non Cash Items | $15,941 | $18,334 | $23,074 | $380,892 |
| Stock Based Compensation | $7,626,676 | $10,175,688 | $2,962,577 | $3,572,960 |
| Depreciation Amortization Depletion | $72,685 | $265,923 | $177,006 | $156,731 |
| Depreciation And Amortization | $72,685 | $265,923 | $177,006 | $156,731 |
| Amortization Cash Flow | $0 | $149,925 | $60,184 | $60,184 |
| Amortization Of Intangibles | $0 | $149,925 | $60,184 | $60,184 |
| Depreciation | $72,685 | $115,998 | $116,821 | $96,547 |
| Gain Loss On Investment Securities | $-678,319 | $-169,751 | $-129,518 | $-3,481,919 |
| Net Foreign Currency Exchange Gain Loss | $587,304 | $-1,347,078 | $-543,115 | $-2,080,968 |
| Net Income From Continuing Operations | $-24,103,139 | $-26,140,375 | $-20,047,390 | $-22,044,663 |
| Change In Inventory | - | - | $0 | $0 |
Fetched: 2026-07-15